In the largest genetic study of its kind, scientists have identified more than 200 genes associated with depression that could give new insights to researchers looking for treatments to what is the leading cause of disability in the world.
Africans, African Americans, as well as Latinos, still make up less than four percent of individuals included in genome-wide association studies, according to a recent study.
It might not make you “wealthier and wise,” but being early to bed and early to rise is associated with greater wellbeing, according to a new large-scale genetic study looking at the sleep cycle — or whether someone is more likely a morning person or a night owl — and its association with mental health and disease.
23andMe received FDA clearance to report on the two most common genetic variants influencing what is called MUTYH-associated polyposis (MAP), a hereditary colorectal cancer syndrome.
In less than a year 23andMe has surpassed its annual goal in recruiting individuals for the Global Genetics Project, which will help diversify our research database and drive inclusion of understudied populations.
While we take a traditional approach to rigorous scientific inquiry and publishing our findings — we now have more than 110 papers that have appeared in peer-reviewed publications, some of which have taken months and often years to complete — we also occasionally take a lighter approach to sharing insights from customers who have consented to participate in research.
This week, thousands of people will flock to San Diego for one of the most important conferences of the year. No, not Comic-Con — it’s the annual meeting of the American Society of Human Genetics, the flagship conference for scientists who study the human genome.
To ensure that our customers can easily see how their contributions are making a difference, 23andMe has added a new Research Overview page, which will roll out to customers over the next few weeks. On the page, customers can see in one place the latest surveys, new studies and data on how customers are participating in research.
We’re reprinting this interview with Paul Cannon, Ph.D, about treatment for his Parkinson’s as well as updates on 23andMe’s research, that was put together by Tomorrow Edition blogger Benjamin Stecher.
Today, 23andMe is thrilled to announce that we are launching a collaboration with GlaxoSmithKline (GSK) to accelerate our ability to make those novel treatments and cures a reality.
